Meetings - The ASCO Post

Matthew Stenger / April 15 2012 / 2012 Society of Surgical Oncology Cancer Symposium

Neoadjuvant Aromatase Inhibitor Therapy Converts Many Patients to Candidates for Breast-conserving Surgery

The American College of Surgeons Oncology Group (ACOSOG) Z1031 trial examined the effect of neoadjuvant aromatase inhibitor therapy on clinical response and breast-conservation rates in postmenopausal...

Breast Cancer

Matthew Stenger / May 15 2012 / 2012 Society of Surgical Oncology Cancer Symposium

Inhibition of SFRP2 Found to Inhibit Growth of Triple-negative Breast Tumors

Secreted frizzled related protein 2 (SFRP2), a protein that modulates the Wnt signaling pathway and is involved in embryonic development, has been thought to exert a tumor-suppressive effect via inhib...

Hepatobiliary Cancer

Matthew Stenger / May 15 2012 / 2012 Society of Surgical Oncology Cancer Symposium

Regional Infusion of Designer T Cells to Treat Intrahepatic Metastases

Designer T cells are modified from normal T cells to express specific immune receptors that allow them, via antibody-directed recognition or other mechanisms, to kill malignant cells bearing particula...

2012 Society of Surgical Oncology Cancer Symposium

Neoadjuvant Aromatase Inhibitor Therapy Converts Many Patients to Candidates for Breast-conserving Surgery

Inhibition of SFRP2 Found to Inhibit Growth of Triple-negative Breast Tumors

Regional Infusion of Designer T Cells to Treat Intrahepatic Metastases

Follicular Extension in Actinic Keratosis and Invasion in Squamous Cell Carcinoma

COA Practice Impact Report Details Consolidation, Shift of U.S. Cancer Care System Into More Expensive Hospital Setting

Personalized Tumor Vaccine Shows Promise in Advanced Ovarian Cancer

Postmarketing Label Modifications for Cancer Drugs Approved Without Supporting Randomized Controlled Trials

Adjuvant FOLFOX or CAPOX for 3 or 6 Months in Stage II or III Colon Cancer

AACR 2018: Pilot Study of Neoadjuvant Nivolumab in Resectable NSCLC

A Gleason 6 Tumor: Is It Cancer, and Should It Be Treated?

FDA Approves Nivolumab/Ipilimumab Combination in Intermediate- or Poor-Risk Advanced RCC

FDA Approves Osimertinib for First-Line Treatment of Metastatic NSCLC With Most Common EGFR Mutations

Pembrolizumab Monotherapy in NSCLC Meets Primary Endpoint in Phase III KEYNOTE-042 Study